HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced today that it is commencing an underwritten public offering of shares of its common stock or common stock equivalents. The company stated that all securities will be offered by HeartBeam, with the final size and terms subject to market conditions. Titan Partners, a division of American Capital Partners, is acting as sole bookrunner for the offering.
The company intends to use the net proceeds from the offering to advance the commercialization of its FDA-cleared 12-lead synthesized ECG system, further develop its extended-wear patch and heart attack detection initiatives, enhance its AI capabilities, and support working capital and general corporate purposes. This capital raise is a strategic move to accelerate HeartBeam's growth and bring its innovative cardiac monitoring solutions to a broader market.
HeartBeam's technology is designed to be the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform aims to enable portable devices that can be used wherever the patient is, delivering actionable heart intelligence to physicians. The goal is to allow physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility, redefining cardiac health management.
The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received clearance in December 2025. HeartBeam holds over 20 issued patents related to its technology enablement, underscoring its commitment to innovation in cardiac care.
The announcement comes as HeartBeam focuses on expanding its presence in the cardiac monitoring market. The company's extended-wear patch and heart attack detection initiatives represent significant opportunities for improving patient outcomes by enabling continuous monitoring and early detection of cardiac events. Additionally, enhancing AI capabilities is expected to improve the accuracy and utility of the synthesized ECG data, providing physicians with better tools for diagnosis and treatment.
Investors and industry observers will be watching the offering closely to gauge market appetite for HeartBeam's stock and the company's ability to execute its commercialization strategy. The success of this offering could provide the necessary capital to drive growth and solidify HeartBeam's position in the medtech space.
For more details on the offering, the full press release is available at https://ibn.fm/pxFOz. Additional information about HeartBeam and its latest news can be found in the company's newsroom at https://ibn.fm/BEAT.
